TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Collaborative Care Program to Improve Depression Treatment in Cardiac Patients
Brief Summary: Depression in cardiac patients is common, persistent, and deadly. However, the vast majority of cardiac patients with depression go unrecognized and untreated, despite the existence of treatments that clearly improve depressive symptoms and may favorably impact survival. Our research group and others have found that depression recognition and treatment appears particularly limited among patients with acute cardiac illness, though this population may be the most vulnerable to the deleterious effects of depression. We propose a project, building on successful collaborative care depression management programs in outpatient settings, to address this important issue.

The specific hypotheses behind the proposed research are that a collaborative care depression management program can be successfully adapted to inpatient cardiac units, and that such a program will lead to greater rates of adequate depression treatment and improvements in secondary outcomes.

The following specific aims capture the stepwise goals of this program:

1. To determine whether a collaborative care depression management program ('Enhanced Care') leads to significantly increased rates of adequate depression treatment compared to usual care (screening and feedback) (Primary Aim).
2. To assess whether this Enhanced Care program has a lasting impact on adequate depression treatment, depressive symptoms, health-related quality of life, and adherence to medical recommendations at 6 weeks, 12 weeks, and 6 months, compared to usual care.


Options:
A: Arm Label: Clinical Management; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: CBT + WBT; Type: EXPERIMENTAL; Interventions: Behavioral: CBT in combination with WBT and life style modification | Intervention Type: BEHAVIORAL; Name: CBT in combination with WBT and life style modification; Assigned to Arm(s): CBT + WBT
B: Arm Label: Collaborative Care; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative Care Treatment | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Treatment | Intervention Type: BEHAVIORAL; Name: Collaborative Care Treatment; Assigned to Arm(s): Collaborative Care | Intervention Type: BEHAVIORAL; Name: Usual Care Treatment; Assigned to Arm(s): Usual Care
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Psycho edcuactional support; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducational support | Intervention Type: BEHAVIORAL; Name: Psychoeducational support; Assigned to Arm(s): Psycho edcuactional support
D: Arm Label: Cohort 1; Type: N/A; Interventions: N/A | Arm Label: Cohort 2; Type: N/A; Interventions: N/A | Arm Label: Cohort 3; Type: N/A; Interventions: N/A | Arm Label: Cohort 4; Type: N/A; Interventions: N/A | Arm Label: Cohort 5; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Collaborative Care Program to Improve Depression Treatment in Cardiac Patients
Brief Summary: Depression in cardiac patients is common, persistent, and deadly. However, the vast majority of cardiac patients with depression go unrecognized and untreated, despite the existence of treatments that clearly improve depressive symptoms and may favorably impact survival. Our research group and others have found that depression recognition and treatment appears particularly limited among patients with acute cardiac illness, though this population may be the most vulnerable to the deleterious effects of depression. We propose a project, building on successful collaborative care depression management programs in outpatient settings, to address this important issue.

The specific hypotheses behind the proposed research are that a collaborative care depression management program can be successfully adapted to inpatient cardiac units, and that such a program will lead to greater rates of adequate depression treatment and improvements in secondary outcomes.

The following specific aims capture the stepwise goals of this program:

1. To determine whether a collaborative care depression management program ('Enhanced Care') leads to significantly increased rates of adequate depression treatment compared to usual care (screening and feedback) (Primary Aim).
2. To assess whether this Enhanced Care program has a lasting impact on adequate depression treatment, depressive symptoms, health-related quality of life, and adherence to medical recommendations at 6 weeks, 12 weeks, and 6 months, compared to usual care.


Options:
A: Arm Label: Collaborative Care; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative Care Treatment | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Treatment | Intervention Type: BEHAVIORAL; Name: Collaborative Care Treatment; Assigned to Arm(s): Collaborative Care | Intervention Type: BEHAVIORAL; Name: Usual Care Treatment; Assigned to Arm(s): Usual Care
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative depression care management | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced usual care | Intervention Type: BEHAVIORAL; Name: Collaborative depression care management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Enhanced usual care; Assigned to Arm(s): 2
C: Intervention Type: BEHAVIORAL; Name: care management; Assigned to Arm(s): N/A
D: Arm Label: Assistance with Pain Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Assistance with Pain treatment | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Assistance with Pain treatment; Assigned to Arm(s): Assistance with Pain Treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Masked Clinical Trial of Phacoemulsification Compared With Phacoemulsification and Micro-Bypass Stent Implantation in Patients With POAG
Brief Summary: This was a prospective, double-masked, 15-month clinical trial comparing efficacy of phacoemulsification alone to combined phacoemulsification and implantation of the iStent® trabecular micro-bypass stent in patients with primary open-angle glaucoma.


Options:
A: Arm Label: iStent; Type: ACTIVE_COMPARATOR; Interventions: Device: iStent | Arm Label: Drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Travoprost | Intervention Type: DEVICE; Name: iStent; Assigned to Arm(s): iStent | Intervention Type: DRUG; Name: Travoprost; Assigned to Arm(s): Drug
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: phacoemulsification alone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: iStent Trabecular Micro-Bypass Stent | Intervention Type: PROCEDURE; Name: phacoemulsification alone; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: iStent Trabecular Micro-Bypass Stent; Assigned to Arm(s): 2
C: Arm Label: A--iStent plus Cataract Surgery; Type: ACTIVE_COMPARATOR; Interventions: Device: iStent plus Cataract Surgery | Arm Label: B--Cataract Surgery Only; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cataract surgery only | Intervention Type: DEVICE; Name: iStent plus Cataract Surgery; Assigned to Arm(s): A--iStent plus Cataract Surgery | Intervention Type: PROCEDURE; Name: Cataract surgery only; Assigned to Arm(s): B--Cataract Surgery Only
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Glaucoma Surgery | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Procedure: cataract surgery only | Intervention Type: DEVICE; Name: Glaucoma Surgery; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: cataract surgery only; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1, Randomized, Open-Label, Parallel Group, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole Modified Release Capsules (30 mg and 60 mg) in Adolescents With Symptomatic Gastroesophageal Reflux Disease
Brief Summary: The purpose of this study is to asses the pharmacokinetics and safety of dexlansoprazole modified release (MR), once daily (QD), in adolescent subjects (age 12-17 years old) with Symptomatic Gastroesophageal Reflux Disease.


Options:
A: Arm Label: Dexlansoprazole MR 30 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Dexlansoprazole MR | Arm Label: Dexlansoprazole MR 60 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Dexlansoprazole MR | Intervention Type: DRUG; Name: Dexlansoprazole MR; Assigned to Arm(s): Dexlansoprazole MR 30 mg QD | Intervention Type: DRUG; Name: Dexlansoprazole MR; Assigned to Arm(s): Dexlansoprazole MR 60 mg QD
B: Intervention Type: DRUG; Name: Esomeprazole (Nexium); Assigned to Arm(s): N/A
C: Arm Label: Open Label Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Open Label Run In Esomeprazole | Arm Label: Double Blind Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Double Blind Esomeprazole | Arm Label: Double Blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double Blind Placebo | Intervention Type: DRUG; Name: Open Label Run In Esomeprazole; Assigned to Arm(s): Open Label Esomeprazole | Intervention Type: DRUG; Name: Double Blind Esomeprazole; Assigned to Arm(s): Double Blind Esomeprazole | Intervention Type: DRUG; Name: Double Blind Placebo; Assigned to Arm(s): Double Blind Placebo
D: Arm Label: Low dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid suspension | Arm Label: High dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid suspension | Intervention Type: DRUG; Name: pantoprazole sodium enteric-coated spheroid suspension; Assigned to Arm(s): High dose, Low dose

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1, Randomized, Open-Label, Parallel Group, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole Modified Release Capsules (30 mg and 60 mg) in Adolescents With Symptomatic Gastroesophageal Reflux Disease
Brief Summary: The purpose of this study is to asses the pharmacokinetics and safety of dexlansoprazole modified release (MR), once daily (QD), in adolescent subjects (age 12-17 years old) with Symptomatic Gastroesophageal Reflux Disease.


Options:
A: Arm Label: Dexlansoprazole MR 30 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Dexlansoprazole MR | Arm Label: Dexlansoprazole MR 60 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Dexlansoprazole MR | Intervention Type: DRUG; Name: Dexlansoprazole MR; Assigned to Arm(s): Dexlansoprazole MR 30 mg QD | Intervention Type: DRUG; Name: Dexlansoprazole MR; Assigned to Arm(s): Dexlansoprazole MR 60 mg QD
B: Arm Label: Rabeprazole 0.5 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: rabeprazole | Arm Label: Rabeprazole 1.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: rabeprazole | Intervention Type: DRUG; Name: rabeprazole; Assigned to Arm(s): Rabeprazole 0.5 mg/kg | Intervention Type: DRUG; Name: rabeprazole; Assigned to Arm(s): Rabeprazole 1.0 mg/kg
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid | Intervention Type: DRUG; Name: pantoprazole sodium enteric-coated spheroid; Assigned to Arm(s): 1, 2, 3
D: Arm Label: Gastrotuss; Type: EXPERIMENTAL; Interventions: Drug: Gastrotuss | Arm Label: Thickened Formula; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: thickened milk | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Gastrotuss; Assigned to Arm(s): Gastrotuss | Intervention Type: DIETARY_SUPPLEMENT; Name: thickened milk; Assigned to Arm(s): Thickened Formula

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of Early Versus Standard Postpartum Insertion of the Etonogestrel Contraceptive Implant
Brief Summary: A highly effective single rod contraceptive implant is now available for use in the US. Delays in the insertion of the device until later in the postpartum period may negatively impact initiation rates. The objective of this study is to compare outcomes of early postpartum insertion (prior to postpartum hospital discharge) of the etonogestrel-releasing contraceptive implant with routine postpartum insertion at 4-8 weeks after delivery. Primary outcome of interest will be time to lactogenesis. Secondary outcomes will include rates of breastfeeding supplementation, infant growth, vaginal bleeding patterns, incidence of side effects, time to resume sexual intercourse after delivery, and incidence of missed routine postpartum follow-up. In addition, a subset of patients who randomize to early postpartum insertion will have expressed breastmilk ascertained for nutrient composition.


Options:
A: Arm Label: Levonorgestrel (LNG) implants immediately postpartum; Type: ACTIVE_COMPARATOR; Interventions: Device: Jadelle | Arm Label: Levonorgestrel (LNG) implants 6 weeks postpartum; Type: ACTIVE_COMPARATOR; Interventions: Device: Jadelle | Intervention Type: DEVICE; Name: Jadelle; Assigned to Arm(s): Levonorgestrel (LNG) implants immediately postpartum | Intervention Type: DEVICE; Name: Jadelle; Assigned to Arm(s): Levonorgestrel (LNG) implants 6 weeks postpartum
B: Arm Label: PostPlacental IUD insertion; Type: EXPERIMENTAL; Interventions: Device: Copper T intrauterine device | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Copper T intrauterine device; Assigned to Arm(s): PostPlacental IUD insertion
C: Arm Label: postplacental insertion after cesarean; Type: EXPERIMENTAL; Interventions: Device: Levonorgestrel-releasing intrauterine system (LNG-IUS) | Arm Label: delayed insertion group; Type: ACTIVE_COMPARATOR; Interventions: Device: Levonorgestrel-releasing intrauterine system (LNG-IUS) | Intervention Type: DEVICE; Name: Levonorgestrel-releasing intrauterine system (LNG-IUS); Assigned to Arm(s): postplacental insertion after cesarean | Intervention Type: DEVICE; Name: Levonorgestrel-releasing intrauterine system (LNG-IUS); Assigned to Arm(s): delayed insertion group
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Etonogestrel contraceptive implant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etonogestrel contraceptive implant | Intervention Type: DRUG; Name: Etonogestrel contraceptive implant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Etonogestrel contraceptive implant; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of Early Versus Standard Postpartum Insertion of the Etonogestrel Contraceptive Implant
Brief Summary: A highly effective single rod contraceptive implant is now available for use in the US. Delays in the insertion of the device until later in the postpartum period may negatively impact initiation rates. The objective of this study is to compare outcomes of early postpartum insertion (prior to postpartum hospital discharge) of the etonogestrel-releasing contraceptive implant with routine postpartum insertion at 4-8 weeks after delivery. Primary outcome of interest will be time to lactogenesis. Secondary outcomes will include rates of breastfeeding supplementation, infant growth, vaginal bleeding patterns, incidence of side effects, time to resume sexual intercourse after delivery, and incidence of missed routine postpartum follow-up. In addition, a subset of patients who randomize to early postpartum insertion will have expressed breastmilk ascertained for nutrient composition.


Options:
A: Arm Label: Postplacental IUD insertion; Type: EXPERIMENTAL; Interventions: Device: Levonorgestrel-releasing IUD (Mirena) | Arm Label: Delayed IUD insertion; Type: ACTIVE_COMPARATOR; Interventions: Device: Levonorgestrel-releasing IUD (Mirena) | Intervention Type: DEVICE; Name: Levonorgestrel-releasing IUD (Mirena); Assigned to Arm(s): Delayed IUD insertion, Postplacental IUD insertion
B: Arm Label: Study Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Combined estrogen-progestin pill | Arm Label: Study Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progestin-only pill | Intervention Type: DRUG; Name: Combined estrogen-progestin pill; Assigned to Arm(s): Study Arm A | Intervention Type: DRUG; Name: Progestin-only pill; Assigned to Arm(s): Study Arm B
C: Arm Label: Counseling for LAM; Type: ACTIVE_COMPARATOR; Interventions: Drug: Counseling for LAM+ LNG-EC | Arm Label: Counseling for LAM+ LNG-EC; Type: EXPERIMENTAL; Interventions: Drug: Counseling for LAM+ LNG-EC | Intervention Type: DRUG; Name: Counseling for LAM+ LNG-EC; Assigned to Arm(s): Counseling for LAM, Counseling for LAM+ LNG-EC
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Etonogestrel contraceptive implant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etonogestrel contraceptive implant | Intervention Type: DRUG; Name: Etonogestrel contraceptive implant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Etonogestrel contraceptive implant; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
Brief Summary: This study is designed to provide safety and efficacy data to support the development of CP-690,550 in patients with moderate to severe rheumatoid arthritis on background of methotrexate.


Options:
A: Arm Label: Active 5mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Sequence 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 5mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 10 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 2
B: Arm Label: Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Sequence 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: CP-690,550 | Arm Label: Sequence 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 3 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 4 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 4
C: Arm Label: Group I: Placebo + Methotrexate (MTX); Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Other: Placebo, Drug: methotrexate (MTX) | Arm Label: Group II: Golimumab + Methotrexate (MTX); Type: PLACEBO_COMPARATOR; Interventions: Drug: Golimumab, Other: Placebo, Drug: methotrexate (MTX) | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX) | Intervention Type: DRUG; Name: methotrexate (MTX); Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX)
D: Arm Label: ETN Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: ETN Alone | Arm Label: ETN+MTX; Type: ACTIVE_COMPARATOR; Interventions: Drug: ETN+MTX | Intervention Type: DRUG; Name: ETN Alone; Assigned to Arm(s): ETN Alone | Intervention Type: DRUG; Name: ETN+MTX; Assigned to Arm(s): ETN+MTX

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of IIb Preserving Neck Dissection VS Neck Dissections Involving IIb Removal (Selective/Functional) in Patients With N0 Neck With Oral Cavity Malignancies
Brief Summary: The treatment of clinically N0 neck in malignancies of oral cavity is controversial. The options include the policy of "wait and watch"(close observation and follow-up), elective irradiation of the neck, elective surgery of the neck (neck dissection).

In elective neck dissections, the procedures commonly performed are modified radical neck dissection-III (functional neck dissection) and selective (supraomohyoid) neck dissection depending on the site of the primary lesion within the oral cavity. There are no trials of IIb preserving neck dissection in cancers of the oral cavity.


Options:
A: Arm Label: Resection/adjuvant radio(-chemo)therapy; Type: EXPERIMENTAL; Interventions: Procedure: Resection, Radiation: Radiotherapy, Drug: Chemotherapy | Arm Label: Adjuvant radio(-chemo)therapy/salvage neck dissection; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy, Drug: Chemotherapy, Procedure: Salvage neck dissection | Intervention Type: PROCEDURE; Name: Resection; Assigned to Arm(s): Resection/adjuvant radio(-chemo)therapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Adjuvant radio(-chemo)therapy/salvage neck dissection, Resection/adjuvant radio(-chemo)therapy | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Adjuvant radio(-chemo)therapy/salvage neck dissection, Resection/adjuvant radio(-chemo)therapy | Intervention Type: PROCEDURE; Name: Salvage neck dissection; Assigned to Arm(s): Adjuvant radio(-chemo)therapy/salvage neck dissection
B: Arm Label: Radiotherapy plus or minus Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy | Arm Label: Transoral Robotic Surgery + Neck Dissection; Type: EXPERIMENTAL; Interventions: Procedure: Transoral Robotic Surgery + Neck Dissection | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Radiotherapy plus or minus Chemotherapy | Intervention Type: PROCEDURE; Name: Transoral Robotic Surgery + Neck Dissection; Assigned to Arm(s): Transoral Robotic Surgery + Neck Dissection
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Selective neck dissection | Arm Label: 2; Type: OTHER; Interventions: Procedure: Conventional Neck dissection | Intervention Type: PROCEDURE; Name: Selective neck dissection; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Conventional Neck dissection; Assigned to Arm(s): 2
D: Arm Label: Group 1 (Not 2B); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Selective Neck Dissection Excluding Level 2B | Arm Label: Group 2 (2B); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Selective Neck Dissection Including Level 2B | Intervention Type: PROCEDURE; Name: Selective Neck Dissection Excluding Level 2B; Assigned to Arm(s): Group 1 (Not 2B) | Intervention Type: PROCEDURE; Name: Selective Neck Dissection Including Level 2B; Assigned to Arm(s): Group 2 (2B)

Answer: C